Evidence map›Paper›PMID 25246883›Full record

ArticleInternational journal of health sciences2014

Relation between HLA typing and clinical presentations in Systemic Lupus Erythematosus patients in Al-Qassim region, Saudi Arabia.

Walid Wadi, Noor Eldeen A M Elhefny, Essam H Mahgoub, Adel Almogren, Khaled D Hamam, Hamad A Al-Hamed, Gasim I Gasim

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of health sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Association ofChinese medical journal · 2018
    Pooled it
  3. Analysis of Nanoparticles' Potential to Induce Autoimmunity.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  4. HLA-DR genotypes in patients with systemic lupus erythematosus in Taiwan.Journal of the Chinese Medical Association : JCMA · 2023
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. HLA-DRB1Frontiers in medicine · 2020
    Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Walid WadiDepartment of Internal Medicine, College of Medicine, Qassim University, Qassim, Saudi Arabia.
Noor Eldeen A M ElhefnyDepartment of Internal Medicine, Faculty of Medicine, Assiut University, Egypt.
Essam H MahgoubDepartment of Internal Medicine, King Fahad Specialist Hospital, Qassim, Saudi Arabia.
Adel AlmogrenDepartment of Serology, Immunology and Molecular biology, College of Medicine and University Hospitals, King Saud University, Riyadh, Saudi Arabia.
Khaled D HamamDepartment of Serology, Immunology and Molecular biology, College of Medicine and University Hospitals, King Saud University, Riyadh, Saudi Arabia.
Hamad A Al-HamedDepartment of Internal Medicine, King Fahad Specialist Hospital, Qassim, Saudi Arabia.
Gasim I GasimDepartment of Internal Medicine, College of Medicine, Qassim University, Qassim, Saudi Arabia.
Assiut University · EGQassim University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSystemic lupus erythematosus (SLE) is a disease with diverse clinical presentations due to interaction between genetic and environmental factors. SLE is associated worldwide with polymorphisms at various loci, including the major histocompatibility complex (MHC), although inconsistencies exist among these studies.

aimsThis study was carried out to investigate, the association of HLA-DRB1, DRB3, DRB4, DRB5, and DQB1 alleles in SLE patients and clinical presentations at Qassim, Saudi Arabia.

methodsFifty one patients with SLE-84.3% of whom had kidney involvement were studied in a case control study for HLA-DRB1, DRB3, DRB4, DRB5, and DQB1.

resultsIt was found that DRB3 is a protective gene among Saudi's against SLE, HLA DRB3, HLA DRB1*11 frequency was increased in patients with serositis with a p value of (0.004), (0.047) respectively, increased frequency of HLA DQB1*3 among SLE patients with skin manifestations with a p value of (0.041), the frequency of HLA DRB1*15 alleles was increased among SLE patients with nephritis with a p value of (0.029), the frequency of HLA DRB1*11 among those with hematological manifestations with a p value of (0.03) and the frequency DRB1*10 was found to be increased among SLE patients with neurological manifestations with a p value of (0.002).

conclusionIn contradistinction to what have been found among other populations DRB3 is a protective gene among Saudi's against SLE. No evidence for a role of the HLA-DRB1, DRB4, DRB5, DQB1 alleles. There was an increased HLA DRB3 frequency with serositis, DQB1*3 skin manifestations, HLA DRB1*15 with nephritis, DRB1*10 with hematological manifestations and DRB1*11 with neurological manifestations.

Indexed as

disease clinical expressionHLAlupusSaudiSLE

Identifiers

PMID25246883
PMCPMC4166988
OpenAlexW2000291652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.